RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hangzhou Tigermed Consulting Co Stock

Hangzhou Tigermed Consulting Co P/E 2024

Hangzhou Tigermed Consulting Co P/E

33.58

Ticker

300347.SZ

ISIN

CNE100001KV8

As of Aug 2, 2024, Hangzhou Tigermed Consulting Co's P/E ratio was 33.58, a -4.63% change from the 35.21 P/E ratio recorded in the previous year.

The Hangzhou Tigermed Consulting Co P/E history

Hangzhou Tigermed Consulting Co Aktienanalyse

What does Hangzhou Tigermed Consulting Co do?

Hangzhou Tigermed Consulting Co Ltd is a leading Chinese company in the field of clinical research and medical services. The company was founded in Hangzhou in 2004 and has since experienced rapid development. Today, the company has branches in over 20 countries and employs over 11,000 people worldwide. Hangzhou Tigermed's business model is based on supporting the entire value chain of clinical trials, from planning and execution to statistical analysis and data interpretation. The company works closely with global actors from the pharmaceutical industry, biomedical research institutions, and regulatory authorities to meet international standards for clinical studies. Over the years, Hangzhou Tigermed has expanded its business activities to include various areas such as data management, biostatistics, medical translation, clinical monitoring, drug safety monitoring, and traceability. An important part of Hangzhou Tigermed's business model is the ability to use high-tech platforms and IT systems to enable real-time monitoring and communication during a clinical trial. This allows the company to quickly respond to adverse events and monitor the progress of the study in real-time. The company also offers specialized services, such as the evaluation of oncology studies and the conduct of studies in the field of traditional Chinese medicine. In addition, Hangzhou Tigermed also has its own pharmaceutical research department specializing in the development of innovative drugs. The company has built strong research and development capabilities, with a focus on open innovation projects and partnerships with research institutions and pharmaceutical companies. In collaboration with its industry partners, Hangzhou Tigermed has conducted a number of research projects that have led to significant innovations in medicine. Hangzhou Tigermed also has a strong presence in the international market, particularly in North America and Europe. Through its branches in these regions, the company is able to offer comprehensive collaboration to its customers on a global level. Overall, Hangzhou Tigermed Consulting Co Ltd has established itself as a significant force in the clinical research industry. The company has developed a wide range of services to meet the needs of its customers in the industry. Hangzhou Tigermed's ability to work closely with its customers and adhere to global standards has helped it become a preferred partner for clinical studies and innovative research projects worldwide. Hangzhou Tigermed Consulting Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Hangzhou Tigermed Consulting Co's P/E Ratio

The Price to Earnings (P/E) Ratio of Hangzhou Tigermed Consulting Co is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Hangzhou Tigermed Consulting Co's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Hangzhou Tigermed Consulting Co is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Hangzhou Tigermed Consulting Co’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Hangzhou Tigermed Consulting Co stock

What is the price-to-earnings ratio of Hangzhou Tigermed Consulting Co?

The price-earnings ratio of Hangzhou Tigermed Consulting Co is currently 33.58.

How has the price-earnings ratio of Hangzhou Tigermed Consulting Co changed compared to last year?

The price-to-earnings ratio of Hangzhou Tigermed Consulting Co has increased by -4.63% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Hangzhou Tigermed Consulting Co high compared to other companies?

Yes, the price-to-earnings ratio of Hangzhou Tigermed Consulting Co is high compared to other companies.

How does an increase in the price-earnings ratio of Hangzhou Tigermed Consulting Co affect the company?

An increase in the price-earnings ratio of Hangzhou Tigermed Consulting Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Hangzhou Tigermed Consulting Co affect the company?

A decrease in the price-earnings ratio of Hangzhou Tigermed Consulting Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Hangzhou Tigermed Consulting Co?

Some factors that influence the price-earnings ratio of Hangzhou Tigermed Consulting Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Hangzhou Tigermed Consulting Co pay?

Over the past 12 months, Hangzhou Tigermed Consulting Co paid a dividend of 0.55 CNY . This corresponds to a dividend yield of about 1.05 %. For the coming 12 months, Hangzhou Tigermed Consulting Co is expected to pay a dividend of 0.6 CNY.

What is the dividend yield of Hangzhou Tigermed Consulting Co?

The current dividend yield of Hangzhou Tigermed Consulting Co is 1.05 %.

When does Hangzhou Tigermed Consulting Co pay dividends?

Hangzhou Tigermed Consulting Co pays a quarterly dividend. This is distributed in the months of July, June, August, August.

How secure is the dividend of Hangzhou Tigermed Consulting Co?

Hangzhou Tigermed Consulting Co paid dividends every year for the past 14 years.

What is the dividend of Hangzhou Tigermed Consulting Co?

For the upcoming 12 months, dividends amounting to 0.6 CNY are expected. This corresponds to a dividend yield of 1.14 %.

In which sector is Hangzhou Tigermed Consulting Co located?

Hangzhou Tigermed Consulting Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hangzhou Tigermed Consulting Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hangzhou Tigermed Consulting Co from 7/12/2024 amounting to 0.568 CNY, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did Hangzhou Tigermed Consulting Co pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Hangzhou Tigermed Consulting Co in the year 2023?

In the year 2023, Hangzhou Tigermed Consulting Co distributed 0.5 CNY as dividends.

In which currency does Hangzhou Tigermed Consulting Co pay out the dividend?

The dividends of Hangzhou Tigermed Consulting Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hangzhou Tigermed Consulting Co

Our stock analysis for Hangzhou Tigermed Consulting Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hangzhou Tigermed Consulting Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.